Semaglutide’s Patent Cliff Isn’t a Generics Story — It’s a Market Architecture Story
As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...
Generics Strategy
As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...